Enbrel

This is a look at a small but intriguing study investigating a new treatment for Alzheimer's disease disease.Brains in Alzheimer's disease are damaged by long-term inflammation of the brain. The progressive deterioration of memory and the ability to perform the tasks that must have a memory function be felt gradually in these patients and their families. Several million Americans should be to develop Alzheimer's disease in the coming decades. Effective treatments are currently poor and ineffective, and new treatments are vital for patients and their families.

Alzheimer's disease is a result of inflammation demntia damagein and the brain. The damage and inflammation occurs due to a variety of chemicals that the body produces to other purposes. A specific chemical called TNF-alpha is considered a major cause of brain inflammation that occurs in Alzheimer's disease. TNF-alpha is a protein molecule produced by white blood cells that stimulates and activates the immune response to cancer or certain infections. Too much TNF-alpha compound that is supposed to lead to autoimmune diseases in which the immune system attacks healthy tissue, such as the joints (rheumatoid arthritis) or skin (psoriasis). New treatments for these diseases using drugs that stopTNF alpha activity, which reduces inflammation reactions.

Since 1998, etanercept (Enbrel aka), a potent TNF-blocking drug has been approved for human use, rheumatoid arthritis as a public servant from accepting indication. Etanercept is now used for many diseases that involve other excesss TNF activity. Etanercept hooks anti-TNF-alpha and judgments of TNF-alpha receptors on cell surfaces. The blocking effect reduces the inflammatory effects of excess TNF-alpha. Researchers and doctors now have extensive experience using etanercept to treat a variety of inflammatory disorders where TNF-alpha activity is expected to play a role. Diseases such as psoriasis and Crohn's disease, in addition to rheumatoid arthritis are examples of diseases that etanercept is used.

A fascinating recent study, the Department of Neurology, USC School of Medicine injections of etanercept (Enbrel) in the posterior neck. This injection site was used to improve the delivery of drugs into the brain, where it was hoped that its anti-inflammatory to take effect. The study included 15 patients who were injected weekly for six months. posterior neck injection of etanercept resulted in sustained cognitive improvement for patients suffering from Alzheimer's disease, which ranged from mild to severe. Other recent studies have also supported the idea that TNF plays a major role in inflammation of the brain of Alzheimer's disease.

The authors of the study the Department of Neurology, USC School of Medicine has noted an unexpected and dramatic clinical outcome (which recurred in the majority of patients who were treated with etanercept). The spectacular repeatedly observed, but the response has been a noticeable improvement within minutes following injection perispinal etanercept. The rapid clinical improvement in memory and symptoms required the authors of the study to add new test procedures to their protocol so they can measure improvements.

A case report of an old man aged 81 years markedimprovement described in 2:00. Improvements included details of the interview toremember capacity, improving the ability to make simple calculations, the ability to be better directed to where it was and what time it was. The man continued to show improvement in the level of brain function including memory and performance tasks throughout the duration of the study and a 14-day monitoring period. family members of elderly patients have also reported that they had noticed an improvement in the PAT.